Lyell Immunopharma, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Lyell announced an $80.0 million private placement from existing and new investors in November 2026. The company reported Q3 2026 results with updated ronde-cel clinical data showing 91% overall response rate and 77% complete response rate in 44 efficacy-evaluable patients from the PiNACLE pivotal trial for 3L+ R/R LBCL; median duration of complete response and median progression-free survival not reached, with 92% continued complete response at 6 months and 75% at 12 months. PiNACLE pivotal data expected mid-2027 with BLA submission in H2 2027. Cash position (including placement proceeds) expected to fund operations into 2028.
Why this rating
Financing + strong Phase data significantly de-risks timeline. $80M raises runway 35% above current $194M cash. Clinical results support BLA pathway, but pre-commercial stage remains high-risk relative to $129M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.